Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | ABP 959 - (SOLIRIS biosimilar) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Intravenous | Hematology | |
| Amgen Inc. | Otezla (apremilast) - (DISCREET) | Moderate to severe genital psoriasis | Phase 3 | oral | #N/A | |
| Amgen Inc. | Tarlatamab (AMG 757) - (DeLLphi-301) | Brain metastasis | Phase 2 | Data Released | Intravenous | Oncology |
| Amgen Inc. | Tezepelumab - (WAYPOINT) | Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Amgen Inc. | Nplate | Chemotherapy-induced thrombocytopenia in gastrointestinal, pancreatic, or colorectal malignancies | Phase 3 | Enrollment Conclusion | Subcutaneous | Hematology |
| Amgen Inc. | TEPEZZA (Teprotumumab) | Thyroid Eye Disease (TED) - chronic | Phase 3 | Intravenous | Opthalmic | |
| Amgen Inc. | OTEZLA (PSA-006) | Psoriatic Arthritis | Phase 3 | Oral | Immunology: Anti-TNF | |
| Amgen Inc. | ABP 654 - (STELARA biosimilar) | Plaque psoriasis | Phase 3 | Ongoing | Subcutaneous | Immunology: Anti-TNF |
